The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
Abstract
BACKGROUND: Age comparisons for incidence, histology, disease stage at initial diagnosis, and mortality of more than 20,000 ovarian cancer patients diagnosed between 1973-1987 are the focus of this descriptive epidemiologic study. This paper highlights key issues and concerns regarding ovarian cancer in women 65 years and older as a frame of reference for the proceedings of the working conference, "Perspectives on Ovarian Cancer in Older-Aged Women," co-sponsored by the National Institute on Aging, National Cancer Institute, and American Cancer Society held at the National Institutes of Health, November, 1991. METHODS: Data are from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics. The SEER Program database represents approximately 9.6% of the U.S. population. RESULTS: Ovarian cancer affects women in the age group 65 years and older more frequently than younger women. More than 48% of all ovarian cancers occur in women in this age group. Age-adjusted rates increase as age advances, peaking at 54.0 per 100,000 in the age group 75-79 years. Time trends also indicate increases in age-specific incidence rates. This malignancy takes its toll in mortality in women 65 years and older with 64% of all deaths due to this neoplasm (in 1989). Moreover, older women are more likely to be initially diagnosed with advanced disease. CONCLUSIONS: Important questions about ovarian cancer in older-aged women need urgent attention from the research community. New strategies for diagnostic leads have to be developed for older women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Cancer: Principles and Practice of Oncology.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-1-142_4 · Cited by 1,068
Projections of the Population of the United States, by Age, Sex, and Race: 1983 to 2080.
Spencer, G. (1984) · U.S. Dept. of Commerce, Bureau of the Census eBooks · Cited by 428
Ovarian cancer: Survival and treatment differences by age
Ries, L. A. G. (2010) · Cancer · doi:10.1002/cncr.2820710206 · Cited by 165
Cancer in the aged. An epidemiologic perspective on treatment issues
Yancik, R., & Ries, L. G. (1991) · Cancer · Cited by 98
Self-citation
Cited by
Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
Parmigiani, G., Berry, D. A., & Aguilar, O. (1998) · The American Journal of Human Genetics · doi:10.1086/301670 · Cited by 753
Ovarian cancer: Epidemiology, biology, and prognostic factors
Holschneider, C. H., & Berek, J. S. (2000) · Seminars in Surgical Oncology · doi:10.1002/1098-2388(200007/08)19:1<3::aid-ssu2>3.0.co;2-s · Cited by 694
Integrated PET/CT: Current Applications and Future Directions
von Schulthess, G. K., Steinert, H. C., & Hany, T. F. (2006) · Radiology · doi:10.1148/radiol.2382041977 · Cited by 619
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Kosary, C. L. (1994) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980100107 · Cited by 417
Long-term trends in cancer mortality in the United States, 1930-1998
Wingo, P. A., Cardinez, C. J., Landis, S. H., Greenlee, R. T., Ries, L. A. G., Anderson, R. N., & Thun, M. J. (2003) · Cancer · doi:10.1002/cncr.11380 · Cited by 385
Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History
Berry, D. A., Parmigiani, G., Sanchez, J., Schildkraut, J., & Winer, E. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.3.227 · Cited by 380
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Ovarian cancer incidence in the United States, 1992–1999
Quirk, J. T., & Natarajan, N. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.02.007 · Cited by 268
Pengetnze, Y., Steed, M., Roby, K. F., Terranova, P. F., & Taylor, C. C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.012 · Cited by 107
Glycoforms of CA125 antigen as a possible cancer marker
Jankovic, M. M., & Milutinovic, B. S. (2008) · Cancer Biomarkers · doi:10.3233/cbm-2008-4104 · Cited by 59
“Although the use of a panel of different tumor markers seems to be very promising for increasing the sensitivity and specificity of ovarian cancer detection and elimination of many false positive results, there is still a need for more spe-cific markers [9,12,13].”
The anti-cancer effects of itraconazole in epithelial ovarian cancer
Choi, C. H., Ryu, J.-Y., Cho, Y.-J., Jeon, H.-K., Choi, J.-J., Ylaya, K., Lee, Y.-Y., Kim, T.-J., Chung, J.-Y., Hewitt, S. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06510-7 · Cited by 53
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Metadata
- Authors
- Yancik, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-08-31
- Volume
- 71
- Issue
- S2
- Pages
- 517-523
- ISSN
- 0008-543X (ISSN-L)
- OpenAlex
- W1983719103
- Cited by
- 309
- References
- 5
- FWCI
- 16.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.